DBV Technologies Pipeline: Investigational Epicutaneous Immunotherapy (EPIT) Programs
DBV Technologies is investigating epicutaneous immunotherapy, an approach that delivers allergens through the skin. Food allergy programs include the VIASKIN® Peanut Patch (DBV712) for peanut allergy and the VIASKIN Milk Patch (DBV135) for cow's milk allergy.1
| Program & Indication | Development Stage | |||||
|---|---|---|---|---|---|---|
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | ||
| Food Allergy | VIASKIN Peanut Patch(DBV712)Peanut Allergy | Ages 4–7 years: Phase 3 | ||||
Ages 1–3 years: Phase 3 | ||||||
Ages 6–12 months*: Phase 2 | ||||||
| VIASKIN Milk Patch(DBV135)Cow's Milk Allergy | Ages 2–17 years: Phase 2 | |||||
| Autoimmune & Inflammatory Disorders | Celiac Disease | Pre-Clinical | ||||
| Multiple Programs | Pre-Clinical | |||||
*Study assessing the achievement of ad-lib consumption of dietary peanut in peanut-allergic infants 6 through 12 months of age following a minimum of 3 years of treatment.1,2
Epicutaneous immunotherapy is under clinical investigation and has not yet been approved by any health or regulatory authority.
Investigational VIASKIN Patch Programs in Peanut Allergy and Cow’s Milk Allergy
VIASKIN Milk Patch
Learn more
Connect With Our Medical Affairs Team
Submit a medical information inquiry or contact your local Medical Science Liaison.
References:
- 1. DBV Technologies. Corporate presentation, July 2026. Accessed November 6, 2026. https://dbv-technologies.com/wp-content/uploads/2026/07/DBV_Investor_Presentation-July_2026.pdf
- 2. DBV Technologies announces first participant screened in THRIVE phase 2 study of the VIASKIN® Peanut Patch in infants ages 6 through 12 months with peanut allergy. Press release, DBV Technologies; June 2, 2026. Accessed November 3, 2026.
Epicutaneous immunotherapy is under clinical investigation and has not yet been approved by any health or regulatory authority.